Lilly Prasugrel Beats Plavix In TRITON, But Bleeding Data Raise Questions

Eli Lilly released powerful efficacy results from an eagerly anticipated Phase III head-to-head trial of its experimental antiplatelet agent prasugrel, which has the potential to take market share from Bristol-Myers Squibb's blockbuster Plavix (clopidogrel)